Blood draw for the laboratory assessment ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 303 | Usher syndrome | 1 |
303. Usher syndrome
Clinical trials : 10 / Drugs : 11 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02065011 (ClinicalTrials.gov) | September 12, 2013 | 14/2/2014 | A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B | An Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B | Usher's Syndrome | Drug: Blood draw for the laboratory assessment | Sanofi | NULL | Active, not recruiting | 18 Years | N/A | All | 9 | Phase 1/Phase 2 | United States;France |